Publications by authors named "Matthew Coghlan"

Claim this Profile
T
Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.
Pallav Bhatnagar, Nadia N Ahmad, Xuan Li, Matthew Coghlan, Lee M Kaplan

Nat Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucose-dependent insulinotropic polypeptide (GIP).
Timo D Müller, Alice Adriaenssens, Bo Ahrén, Matthias Blüher, Andreas L Birkenfeld, Matthew P Coghlan

Mol Metab· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Sound of Safety: DIVOT (Doppler Imaging for Vascular Orientation in Thoracic Procedures) Protocol.
Amy Fraser, Daniel S Brenner, Matthew Coghlan, Heather Andrade, Maya Haouili

POCUS J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice.
Xinxin Yu, Shiuhwei Chen, Jan-Bernd Funcke, Leon G Straub, Valentina Pirro, Matthew P Coghlan

Cell Metab· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreasing delirium through music listening (DDM) in critically ill, mechanically ventilated older adults in the intensive care unit: a two-arm, parallel-group, randomized clinical trial.
Sarah Seyffert, Salwa Moiz, Matthew Coghlan, Patil Balozian, Jason Nasser

Trials· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural determinants of dual incretin receptor agonism by tirzepatide.
Bingfa Sun, Francis S Willard, Dan Feng, Jorge Alsina-Fernandez, Qi Chen, Matthew P Coghlan

Proc Natl Acad Sci U S A· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the Region.
Nicholas Bowker, Robert Hansford, Stephen Burgess, Christopher N Foley, Victoria P W Auyeung, Matthew P Coghlan

Diabetes· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.
Ricardo J Samms, Michael E Christe, Kyla Al Collins, Valentina Pirro, Brian A Droz, Matthew P Coghlan

J Clin Invest· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
Takahiro Kawai, Bingfa Sun, Hitoshi Yoshino, Dan Feng, Yoshiyuki Suzuki, Matthew P Coghlan

Proc Natl Acad Sci U S A· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Francis S Willard, Jonathan D Douros, Maria Bn Gabe, Aaron D Showalter, David B Wainscott, Matthew P Coghlan

JCI Insight· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J Samms, Matthew P Coghlan, Kyle W Sloop

Trends Endocrinol Metab· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice.
David C Hornigold, Emma Roth, Victor Howard, Sarah Will, Stephanie Oldham, Matthew P Coghlan

Appetite· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and characterisation of a novel glucagon like peptide-1 receptor antibody.
Emma K Biggs, Lihuan Liang, Jacqueline Naylor, Shimona Madalli, Rachel Collier, Matthew P Coghlan

Diabetologia· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhalational Anesthetics Induce Neuronal Protein Aggregation and Affect ER Trafficking.
Matthew Coghlan, Elizabeth Richards, Sadiq Shaik, Pablo Rossi, Ramesh Babu Vanama

Sci Rep· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity.
Sarah Will, David C Hornigold, David J Baker, Matthew P Coghlan, Malcolm Mesquita

Curr Opin Pharmacol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats.
James L Trevaskis, Chester Bittencourt Sacramento, Hani Jouihan, Safina Ali, John Le Lay, Matthew P Coghlan

Diabetes· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.
Marcela Herrera, Magnus Söderberg, Alan Sabirsh, Barbara Valastro, Johan Mölne, Matthew Coghlan

Am J Physiol Renal Physiol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists.
Jacqueline Naylor, Arthur T Suckow, Asha Seth, David J Baker, Isabelle Sermadiras, Matthew P Coghlan

Biochem J· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validity of anaesthetic complication coding data as a clinical indicator.
Andrew Jones, John P Monagle, Susan Peel, Matthew W Coghlan, Vangy Malkoutzis

Aust Health Rev· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice.
Maria Sörhede Winzell, Matthew Coghlan, Brendan Leighton, Georgia Frangioudakis, David M Smith

Eur J Pharmacol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulating serine palmitoyl transferase (SPT) expression and activity unveils a crucial role in lipid-induced insulin resistance in rat skeletal muscle cells.
Maria L Watson, Matthew Coghlan, Harinder S Hundal

Biochem J· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucokinase activators in diabetes management.
Matthew Coghlan, Brendan Leighton

Expert Opin Investig Drugs· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter.
Nigel J Pearce, Jonathan R S Arch, John C Clapham, Matthew P Coghlan, Stacey L Corcoran

Metabolism· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators.
Katy J Brocklehurst, Victoria A Payne, Rick A Davies, Debra Carroll, Helen L Vertigan, Matthew P Coghlan

Diabetes· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase.
Katrina MacAulay, Eric Hajduch, Anne S Blair, Matthew P Coghlan, Stephen A Smith

Eur J Biochem· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis